07:22 AM EDT, 07/09/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Wednesday the FDA approved a label update for Kisunla with a revised titration schedule for early symptomatic Alzheimer's disease.

The new regimen lowered ARIA-E risk by 41% at 24 weeks and 35% at 52 weeks, with no reduction in plaque-removal efficacy, the company said.

The dosing modification adjusts the timing of a single vial while keeping the total dosage unchanged by week 24, Eli Lilly ( LLY ) said.

The company also said no new safety issues were identified, though hypersensitivity and infusion-related reactions were more common.